
Traws Pharma (TRAW) Stock Forecast & Price Target
Traws Pharma (TRAW) Analyst Ratings
Bulls say
Traws Pharma is currently seen as a neutral stock, with a reduced conviction due to recent setbacks in its clinical trials by regulatory agencies. The company has reduced visibility on its next value driver, with its influenza program being pushed back due to regulatory concerns. Despite this, the company's focus on its COVID program, along with cost cuts and a strong pipeline of products, may still provide opportunities for growth in the future.
Bears say
Traws Pharma is currently facing significant risks, including financing, clinical trial, regulatory, delisting, and bankruptcy risks. These risks could potentially hinder the company's ability to successfully develop and commercialize its product candidates and generate revenue. While the company has announced the initiation of a hantavirus/Ebola antiviral program, the early development status and uncertainty around the program's potential commercial success limits its current value. Additionally, Traws Pharma's success in the competitive antiviral market will depend on its ability to differentiate its products and secure a sustainable market for COVID, hantavirus, and Ebola.
This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.
Traws Pharma (TRAW) Analyst Forecast & Price Prediction
Start investing in Traws Pharma (TRAW)
Order type
Buy in
Order amount
Est. shares
0 shares